Overview

Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than typical compounds in this respect. We therefore treated healthy non-obese men with olanzapine (atypical AP) or haloperidol (typical AP) for 8 days, and studied the impact of these interventions on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.
Phase:
N/A
Details
Lead Sponsor:
Leiden University Medical Center
Collaborator:
Dutch Diabetes Research Foundation
Treatments:
Antipsychotic Agents
Dopamine
Haloperidol
Haloperidol decanoate
Olanzapine